A handwritten note discovered near his body suggested that financial hardship was a significant factor behind his tragic ...

Citi lowered the firm’s price target on PTC (PTC) to $195 from $200 and keeps a Neutral rating on the shares ahead of the earnings report. The ...

The case gained prominence after PTC News highlighted it, which led the child’s family members—his grandparents and uncle—to ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

PTC PTC underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

Inc., a leading provider of software solutions for product design, manufacturing, and service, continues to navigate a challenging macroeconomic environment while positioning itself for future growth.

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

Barclays analyst Saket Kalia maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $215.00. The company’s ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

The Western US solar fleet is amid rapid growth, with the region being home to four of the top five markets in planned ...